Doctors could eventually use the method to quickly reverse oxygen deprivation.
Susan YoungFollow @twitterapi
I’m the biomedicine editor for MIT Technology Review. I look for stories where technology stands to improve human health or advance our understanding of the human condition.
I joined MIT Technology Review in March 2012 after a brief stint in the Washington, D.C., news bureau of the scientific journal Nature. Before I ventured to the East Coast, I spent several years in the San Francisco Bay Area as a doctoral student in molecular biology and one whirlwind year in science-writing boot camp in Santa Cruz.
In California, I wrote for the Stanford University press offices, the Multiple Sclerosis Discovery Forum, and the Salinas Californian newspaper. I grew up in a small town in eastern Texas, surrounded by bird song, rolling cattle fields, and lanky pine trees. When I’m not exploring health tech, you will probably find me cooking or giggling over an exceptional LOLcat.
Susan Young's Stories
Are new funding models and partnerships between big pharma, biotech, and academia the right cure for the industry?
A big-picture view of microbial DNA should help public health officials, genome scientists, and possibly medical researchers.
Sequencing the microörganisms that inhabit healthy people could aid research into human disease.
The startup's software takes raw genome data and creates a usable report for doctors.
Foundation Medicine will profile tumor genomes for Novartis' cancer drug trials.
Millimeter-scale devices could give surgeons the ability to operate on beating hearts.
A DNA and RNA nanoparticle brings gene-silencing siRNAs to tumor cells.
Spinal stimulation combined with assisted walking therapy generates new neural circuits and restores voluntary leg movement.
One pharmaceutical company aims to lengthen a stroke's drug-treatable period from hours to months.